» Articles » PMID: 37261652

The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review

Overview
Date 2023 Jun 1
PMID 37261652
Authors
Affiliations
Soon will be listed here.
Abstract

Hidradenitis suppurativa (HS) is a skin disease resulting from chronic, recurrent inflammation around hair follicles, characterized by proinflammatory cytokines such as IL-1, IL-17, IL-23, and TNF-α. While adalimumab, a TNF-α targeting human IgG monoclonal antibody, is the only approved treatment for HS, there are many other therapies being investigated now targeting other key players in inflammatory pathways such as the cytokines listed above, C5a in the complement pathway, and Janus kinase (JAK). This review discusses current clinical trials for biologics and small molecules, procedures, and wound dressings undergoing study in hidradenitis suppurativa.

Citing Articles

The potential role of nanobodies in asthma therapy.

Khalid Salah Al-Sheakly B, Saheb Sharif-Askari F, Sharif-Askari N, Hundt J, Halwani R Front Pharmacol. 2025; 15:1510806.

PMID: 39902079 PMC: 11788342. DOI: 10.3389/fphar.2024.1510806.


Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.

Ma X, Zhang S, Ren X, Feng Y, Li H, Chen S Front Immunol. 2024; 15:1434127.

PMID: 39600699 PMC: 11590123. DOI: 10.3389/fimmu.2024.1434127.


Australasian hidradenitis suppurativa management guidelines.

Frew J, Smith A, Penas P, Ellis E, Foley P, Rubel D Australas J Dermatol. 2024; 66(2):75-89.

PMID: 39578415 PMC: 11898165. DOI: 10.1111/ajd.14388.


Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.

Al-Aqtash R, Collier D Channels (Austin). 2024; 18(1):2355150.

PMID: 38762911 PMC: 11110710. DOI: 10.1080/19336950.2024.2355150.

References
1.
Geoghegan L, Rodrigues R, Harrison C, Rodrigues J . The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review. Plast Reconstr Surg Glob Open. 2022; 10(11):e4660. PMC: 9674480. DOI: 10.1097/GOX.0000000000004660. View

2.
Papp K, Szepietowski J, Kircik L, Toth D, Eichenfield L, Leung D . Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021; 85(4):863-872. DOI: 10.1016/j.jaad.2021.04.085. View

3.
Leslie J, Mackey J, Jamieson T, Ramon-Gil E, Drake T, Fercoq F . CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022; . PMC: 9484388. DOI: 10.1136/gutjnl-2021-326259. View

4.
Shaharir S, Jamil A, Chua S, Arumugam M, Rosli N . A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS. Dermatol Ther. 2020; 33(6):e14021. DOI: 10.1111/dth.14021. View

5.
Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B . Metformin use in hidradenitis suppurativa. J Dermatolog Treat. 2019; 31(3):261-263. DOI: 10.1080/09546634.2019.1592100. View